Stockreport

Astria Therapeutics: Too Much Risk, Too Little Reward Despite Near-Term Data Readout [Seeking Alpha]

Astria Therapeutics, Inc.  (ATXS) 
PDF The company has successfully completed a Phase 1 study for STAR-0215, demonstrating positive results in terms of safety, tolerability, and efficacy. Astria is now mov [Read more]